This is a clinically sufficient dose; specifically, a dose of 8‐24 g·day−1 of cholestyramine is usually set for hyperlipidemia patients.39, 40 Cholestyramine also elevated hepatic CYP7A1 expression and fecal total bile acid content, which suggested the mechanism of action occurred through the activation of the cholesterol catabolism pathway. Here, CYP7A1 is linked to hyperlipidemia.